RedHill Biopharma (RDHL) Other Non-Current Assets (2011 - 2025)
RedHill Biopharma (RDHL) posted quarterly Other Non-Current Assets of $169000.0 for Q4 2025, up 14.19% year-over-year from $148000.0 in Q4 2024, and up 5.62% quarter-over-quarter from $160000.0 in Q2 2025.
RedHill Biopharma (RDHL) Other Non-Current Assets (2011 - 2025) Analysis & Trends
RedHill Biopharma (RDHL) has reported Other Non-Current Assets for 15 consecutive years, with $169000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Other Non-Current Assets rose 14.19% year-over-year to $169000.0; the TTM figure through Dec 2025 stood at $169000.0 (up 14.19% YoY), while the FY2025 annual figure was $169000.0, up 14.19% from the prior year.
- Other Non-Current Assets grew to $169000.0 in Q4 2025 per RDHL's latest filing, from $160000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $16.2 million in Q4 2021 and bottomed at $148000.0 in Q4 2024.
- Historically, Other Non-Current Assets has averaged $10.1 million across 5 years, with a median of $16.0 million in 2022.
- Annual changes were most pronounced in 2023 — Other Non-Current Assets plunged 95.06% — and 2025, when it gained 14.19%.
- RedHill Biopharma's Other Non-Current Assets stood at $16.2 million in 2021, then fell by 1.05% to $16.0 million in 2022, then slumped by 95.06% to $790000.0 in 2023, then plunged by 81.27% to $148000.0 in 2024, then increased by 14.19% to $169000.0 in 2025.
- Business Quant data shows RDHL's Other Non-Current Assets at $169000.0 in Q4 2025, $160000.0 in Q2 2025, and $148000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | 56.35 Mn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | 1.79 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | 384.00 Mn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 503.80 Mn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 239.50 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 1.06 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 59.30 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 304.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 13.00 Mn |
| 10 | RedHill Biopharma | 2.05 Bn | 2.05 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 169,000.00 |
| Jun 30, 2025 | 160,000.00 |
| Dec 31, 2024 | 148,000.00 |
| Jun 30, 2024 | 739,000.00 |
| Dec 31, 2023 | 790,000.00 |
| Jun 30, 2023 | 9.14 Mn |
| Mar 31, 2023 | 11.05 Mn |
| Dec 31, 2022 | 16.00 Mn |
| Sep 30, 2022 | 16.00 Mn |
| Jun 30, 2022 | 16.00 Mn |
| Mar 31, 2022 | 16.17 Mn |
| Dec 31, 2021 | 16.17 Mn |
| Sep 30, 2021 | 16.16 Mn |
| Jun 30, 2021 | 16.16 Mn |
| Mar 31, 2021 | 16.16 Mn |
| Dec 31, 2020 | 16.16 Mn |
| Sep 30, 2020 | 16.15 Mn |
| Jun 30, 2020 | 20.15 Mn |
| Mar 31, 2020 | 20.15 Mn |
| Dec 31, 2019 | 152,000.00 |